retatrutide phase 2 nejm 2023 obesity trial results in adults with over 104 weeks in the highest dose group had 30.3% weight loss. Nearly 2/3 reached BMI < 30 1 in 3 reached BMI < 25 2023年度回顧】 NEJM Notable Articles of

I thought since its a smaller amount than what a doctor was giving out, it had to be somewhat safe, and I really had nothing to lose. While certain med spas can provide GLP-1 drugs without taking a trip to the doctors office, Brooks found that ordering online directly from the manufacturer was the most cost effective option

It allows you to focus on the science, confident that your materials won't be a confounding variable

FIGURE 7 Although the funnel plot displayed an asymmetrical distribution, examinations for small-study effects did not provide evidence supporting publication bias

But the biological logic is strong